Clinical Trials Sponsored by Rousselot BVBA

Total 66 results

Rousselot BVBA

Not yet recruiting

An Open Label, Dose-escalation Study, Assessing the Safety and Tolerability of a Collagen Peptide

Tolerance

United States
Rousselot BVBA
BioTeSys GmbH

Active, not recruiting

Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects

Healthy | Prediabetic State

Germany
KU Leuven
Rousselot BVBA

Completed

Effects of Collagen Peptide Supplementation on Muscle and Tendon Damage and Function

Healthy Male Subjects | Exercise

Belgium
Rousselot BVBA
BioTeSys GmbH

Completed

Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects

Bioavailability

Germany
Rousselot BVBA
BioTeSys GmbH

Active, not recruiting

Investigation of the Bioavailability of Marine Based Collagen Peptides in Healthy Subjects

Healthy

Germany
Arthur van Zanten
Rousselot BVBA; Intensive Care Research Foundation, Gelderse Vallei Hospital

Recruiting

The CONFUCIUS Oral Protein Supplementation Trial (CONFUCIUS)

Critical Illness | Intensive Care Unit Acquired Weakness

Netherlands
Tibotec BVBA

Completed

TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)

HIV Infections

South Africa
Tibotec BVBA

Completed

A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

Moderate Hepatic Impairment
Tibotec BVBA

Completed

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

Tuberculosis
Tibotec BVBA

Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Hepatitis C | HIV | Telaprevir
Nealth Sarl
ROUSSELOT SAS

Completed

Biological Bone Markers and Hydrolyzed Collagen Supplement in Menopausal Healthy Women

Osteoporosis

France
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Tibotec BVBA

Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C
Tibotec BVBA

Completed

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Hepatitis C, Chronic

France, United Kingdom, Sweden
Tibotec BVBA

Completed

A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants

Healthy
Tibotec BVBA

Completed

TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions

Healthy Volunteer
Tibotec BVBA

Completed

TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer

HIV | Tuberculosis
Tibotec BVBA

Completed

VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer

Hepatitis C | HIV | HCV | AIDS
Tibotec BVBA

Terminated

TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

Hepatitis C Virus

Poland, Netherlands
Tibotec BVBA

Completed

VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram

Hepatitis C
Tibotec BVBA

Completed

VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

Kidney Diseases | Hepatitis C
MSD Belgium BVBA

Completed

BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium (BEPACT- Lung)

Stage IV Non-small Cell Lung Cancer

Belgium
Versailles Hospital
Pr Philippe ROUSSELOT

Unknown

Second STOP After Pioglitazone Priming in CML Patients (PIO2STOP)

Chronic Myeloid Leukemia (CML)

France
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Janssen Infectious Diseases BVBA

Withdrawn

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Multi-drug Resistant Tuberculosis

China, Ukraine, Taiwan, Korea, Republic of, Peru, Brazil, Estonia, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey, Georgia, Mexico, Cambodia, Ethiopia
Janssen Infectious Diseases BVBA

Completed

A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

Hepatic Impairment

Germany, Czech Republic
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
Janssen Infectious Diseases BVBA

Approved for marketing

Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis

Tuberculosis

Russian Federation, Lithuania
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Janssen Infectious Diseases BVBA

Completed

A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult Participants

Healthy | Biological Availability

Netherlands
TripleMed B.V.
Fakkel bvba

Completed

ANEUFIX for Endoleaks Type II (ACP-T5)

Abdominal Aortic Aneurysm

Netherlands
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Infectious Diseases BVBA

Completed

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Tuberculosis

China, Ukraine, Korea, Republic of, Peru, Estonia, Kenya, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey
Janssen Infectious Diseases BVBA

Completed

A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir

Healthy

Belgium
Janssen Infectious Diseases BVBA

Completed

TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Tuberculosis

South Africa, Peru, Latvia, Philippines, Russian Federation, Thailand, Brazil, India
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir

Healthy Participants

Netherlands
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

Hepatitis C
Universidade Estadual de Londrina
Conselho Nacional de Desenvolvimento Científico e Tecnológico; Rousselot BVBA; Coordination for the Improvement of Higher Education Personnel

Completed

Effects of Whey Protein Supplementation Collagen Associated to Resistance Training in Older Woman

Sarcopenia | Collagen Degeneration

Brazil
Zimmer Biomet
Biomet Belgium BVBA

Completed

Comparison of ARPE Prosthesis With the Literature

Arthritis

Belgium
Prof. Dr. Claus Bachert BVBA

Unknown

Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest (SPTTapeD1)

Allergic Rhinitis | Allergic Conjunctivitis | Food Allergy | Allergic Asthma
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

Healthy Participants
Vertex Pharmaceuticals Incorporated
Tibotec BVBA

Completed

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

Hepatitis C | Opioid-Related Disorders

United States
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Hepatitis C
Universitaire Ziekenhuizen KU Leuven
MSD Belgium BVBA

Recruiting

The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach

Shoulder Pain | Anesthesia

Belgium
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Onze Lieve Vrouw Hospital
Universiteit Antwerpen; MSD Belgium BVBA

Completed

Functional Respiratory Imaging After Neostigmine or Sugammadex (FRINeoS)

Respiratory-Gated Imaging Techniques

Belgium
Arjuna Natural Limited
KU Leuven; ZB Sports Development BVBA

Unknown

The Effects of Ashwagandha in Endurance Exercise Performance

Healthy

Belgium
Yakult Honsha European Research Center, ESV
Harmony Clinical Research BVBA

Completed

Evaluation of New Method for Measuring Stool Consistency

Healthy

Belgium

3

Subscribe